2 Information about daratumumab

Marketing authorisation indication

2.1 Daratumumab (Darzalex, Janssen) has a marketing authorisation as a monotherapy for 'the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedules for both injection and infusion are available in the summary of product characteristics for daratumumab.


2.3 The list prices of daratumumab (excluding VAT; BNF online, accessed January 2022) are:

  • £4,320 per 1,800 mg/15 ml solution for injection vial

  • £360 per 100 mg/5 ml concentrate for solution for infusion vial

  • £1,440 per 400 mg/20 ml concentrate for solution for infusion vial.

2.4 The company has a commercial arrangement. This makes daratumumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)